Search results for "hormone"

showing 10 items of 2056 documents

Association of childhood cancer with factors related to pregnancy and birth

1999

It has been hypothesized that risk factors of childhood cancers may already operate during the prenatal and neonatal period. Results of previous epidemiological studies have been inconsistent.During 1992-1997 a large case-control study on childhood cancers and a variety of potential risk factors was conducted in Germany. Cases were ascertained by the German Childhood Cancer Registry. Each case was matched to a population-based control of the same age and gender, sampled from the district where the case lived at the date of diagnosis. For the analyses, 2358 cases and 2588 controls were available.Risk of childhood acute leukaemia increased with maternal ageor =20 years at time of delivery (od…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHormone Replacement TherapyEpidemiologyBirth weightPopulationBone NeoplasmsSoft Tissue NeoplasmsPrenatal careCentral Nervous System NeoplasmsPregnancyRisk FactorsGermanyOdds RatiomedicineBirth WeightHumansRegistriesRisk factorChildeducationRetrospective Studieseducation.field_of_studyChildhood Cancer RegistryPregnancybusiness.industryLymphoma Non-HodgkinSmokingInfant NewbornCase-control studyInfantGeneral MedicineOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseParityMaternal ExposureChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessMaternal AgeInternational Journal of Epidemiology
researchProduct

Non-Immune Goiter and Hypothyroidism in a 19-Week Fetus: A Plea for Conservative Treatment

2009

Hypothyroidism was documented by cordocentesis at 19 weeks in a fetus with non-immune goiter. Intra-amniotic thyroxine was injected at 25 weeks when amniotic fluid volume increased. Psychomotor outcome was normal. We argue that intra-amniotic thyroxine should not be used to treat the hypothyroidism but only to correct the development of polyhydramnios.

AdultMalePolyhydramniosendocrine systemmedicine.medical_specialtyPediatricsPolyhydramniosGoiterAmniotic fluidendocrine system diseasesLevothyroxineThyrotropinUltrasonography PrenatalThyroid-stimulating hormonePregnancyCongenital HypothyroidismmedicineHumansFetusPregnancyGoiterbusiness.industryAmniotic Fluidmedicine.diseaseSurgeryCongenital hypothyroidismFetal DiseasesThyroxinePregnancy Trimester SecondPediatrics Perinatology and Child HealthFemaleCordocentesisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of Pediatrics
researchProduct

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mi…

1996

Chronic intestinal inflammation induced by 2,4,6,-trinitrobenzene sulfonic acid (TNBS) is characterized by a transmural granulomatous colitis that mimics some characteristics of human Crohn's disease. Here, we show that the transcription factor NF-kappa B p65 was strongly activated in TNBS-induced colitis and in colitis of interleukin-10-deficient mice. Local administration of p65 antisense phosphorothioate oligonucleotides abrogated clinical and histological signs of colitis and was more effective in treating TNBS-induced colitis than single or daily administration of glucocorticoids. The data provide direct evidence for the central importance of p65 in chronic intestinal inflammation and …

AdultMaleProtein subunitMolecular Sequence DataGeneral Biochemistry Genetics and Molecular BiologyMiceCrohn DiseaseAdrenal Cortex HormonesmedicineAnimalsHumansColitisTranscription factorCells CulturedAgedEnterocolitisPhosphorothioate OligonucleotidesBase Sequencebusiness.industryOligonucleotideEnterocolitisNF-kappa BTranscription Factor RelAGeneral MedicineDNAMiddle AgedOligonucleotides Antisensemedicine.diseaseNFKB1digestive system diseasesInterleukin-10Interleukin 10Disease Models AnimalTrinitrobenzenesulfonic AcidImmunologyCancer researchCytokinesFemalemedicine.symptombusinessNature medicine
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting beta(2) agonists. Between 2005 and 2007 280 patients (58% female, mean age 44+/-16 yrs., 46% on oral corticosteroids, median serum IgE level 235IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450mg omalizum…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyAdolescentAllergyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin ESeverity of Illness IndexYoung AdultQuality of lifeAdrenal Cortex HormonesForced Expiratory VolumeGermanyInternal medicineSeverity of illnessHypersensitivityHumansMedicineAnti-Asthmatic AgentsProspective StudiesChildProspective cohort studyAdverse effectAsthmaDose-Response Relationship Drugbiologybusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryTreatment Outcomebiology.proteinFemaleIgETherapybusinessmedicine.drugRespiratory Medicine
researchProduct

Vasopressin receptors involved in adrenergic neurotransmission in the circular muscle of the human vas deferens

1998

We studied the effects of vasopressin on the adrenergic responses of in vitro preparations of circular muscle from the vas deferens obtained from 28 men undergoing elective vasectomy. Vasopressin (3 x 10(-9)-3 x 10(-8) M) enhanced the phasic contractions elicited by electrical field stimulation and noradrenaline. This potentiation was blocked by the vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)vasopressin (10(-6) M) but not by the vasopressin V2 receptor antagonist [d(CH2)5, D-Ile2,Ile4,Arg8]vasopressin (10(-6) M). The Ca2+ antagonist nifedipine (10(-6) M) did not affect the potentiation of electrical field stimulation induced by vasopressin and noradrenaline but reduced KCl-induced con…

AdultMaleReceptors Vasopressinmedicine.medical_specialtyVasopressinNifedipineVasopressinsNeuropeptideAdrenergicStimulationIn Vitro TechniquesSynaptic TransmissionPotassium ChlorideNorepinephrineHormone AntagonistsVas DeferensInternal medicinemedicineHumansVasoconstrictor AgentsVasopressin receptorPharmacologyArginine vasopressin receptor 1BChemistryAntagonistVas deferensMuscle SmoothCalcium Channel BlockersElectric StimulationArginine Vasopressinmedicine.anatomical_structureEndocrinologyAdrenergic alpha-AgonistsAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsMuscle ContractionEuropean Journal of Pharmacology
researchProduct

Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index

2015

The aim of the study is to clarify the relationship between adipose tissue dysfunction, metabolic profile and growth hormone (GH)/insulin-like growth factor (IGF)-I secretion in healthy adult subjects. We investigated the metabolic profile in a cohort of 231 consecutive healthy subjects in relation to GH, IGF-I levels, and visceral adiposity index (VAI). Anthropometric measures, lipid profile, and glucose and insulin levels during oral glucose tolerance test, Homa-IR and ISI Matsuda, IGF-I and GH peak after GHRH plus Arginine test were analyzed. The subjects with high VAI showed lower GH peak (22.8 ± 11.1 vs. 42.2 ± 21.3 µg/L; p = 0.049) and lower IGF-I (presented as IGF-I under normal rang…

AdultMaleRiskmedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissueIntra-Abdominal FatBiologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyMetabolic DiseasesInternal medicineDiabetes mellitusmedicineHealth Status IndicatorsHumansMetabolic riskInsulin-Like Growth Factor IProspective cohort studyGrowth hormoneSubclinical infectionGH deficiencymedicine.diagnostic_testHuman Growth HormoneInsulinGH deficiency; Growth hormone; Metabolic risk; Visceral adiposity; Endocrinology; Endocrinology Diabetes and MetabolismMiddle Agedmedicine.diseaseEndocrinologyBlood pressureCohortFemaleVisceral adiposityLipid profile
researchProduct

Recovery of hormonal, blood lipid, and hematological profiles from a North Pole expedition.

2011

INTRODUCTION This study examined the recovery patterns of hormonal, blood lipid, and hematological profiles following strenuous physical loading, continuous extreme cold exposure and energy deficit induced by a North Pole expedition. METHODS Seven men completed an 850-km North Pole expedition in temperatures varying from -3 degrees C to -47 degrees C. Daily energy intake was approximately 23 MJ x d(-1) and was composed of approximately 60% fat. Blood samples were collected 2 wk before (Pre) the expedition and after 2 wk (Post 1), and 2 mo (Post 2). Additional samples were collected on the first (R1), third (R3), and fifth (R5) return days. RESULTS Mean weight loss upon return was 10 kg. Ene…

AdultMaleSerummedicine.medical_specialtyGlobulinBlood lipidsHematocritWeight lossStress PhysiologicalInternal medicinemedicineHumansExerciseTestosteroneHematologic Testsmedicine.diagnostic_testbiologyArctic RegionsPublic Health Environmental and Occupational HealthCold ClimateLipidsCold TemperatureEndocrinologybiology.proteinHemoglobinmedicine.symptomEnergy MetabolismHormoneLipoproteinAviation, space, and environmental medicine
researchProduct

Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma.

2012

The role of IgE in patients with severe asthma is not fully understood.We sought to investigate whether IgE to Staphylococcus aureus enterotoxins might be relevant to disease severity in adult asthmatic patients.Specific IgE antibody concentrations in serum against enterotoxins, grass pollen (GP), and house dust mite allergens and total IgE levels were measured in adult cohorts of 69 control subjects, 152 patients with nonsevere asthma, and 166 patients with severe asthma. Severe asthma was defined as inadequately controlled disease despite high-dose inhaled corticosteroids plus at least 2 other controller therapies, including oral steroids.Enterotoxin IgE positivity was significantly great…

AdultMaleStaphylococcus aureusImmunologymacromolecular substancesEnterotoxinImmunoglobulin EStaphylococcal infectionsAnti-asthmatic AgentSeverity of Illness IndexFEV1Enterotoxinsimmune system diseasesAdrenal Cortex HormonesRisk FactorsmedicineImmunology and AllergyAnimalsHumansAnti-Asthmatic AgentshospitalizationsAsthmaHouse dust miteEosinophil cationic proteinSuperantigensbiologybusiness.industryasthma severityPyroglyphidaeAtopic dermatitisAllergensImmunoglobulin EMiddle AgedStaphylococcal Infectionsmedicine.diseasebiology.organism_classificationAntibodies BacterialAsthmarespiratory tract diseasesCase-Control StudiesImmunologybiology.proteinPollenFemaleIgEbusinessThe Journal of allergy and clinical immunology
researchProduct